CPC
MDGL icon

Congress Park Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Congress Park Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,200
Closed -$320K – 121
2024
Q1 		$320K Buy
+1,200
New +$283K 0.14% 92
2023
Q1 		– Sell
-800
Closed -$232K – 137
2022
Q4 		$232K Sell
800
-2,450
-75% -$240K 0.14% 122
2022
Q3 		$211K Hold
3,250
– – 0.12% 117
2022
Q2 		$233K Sell
3,250
-10
-0.3% -$735 0.14% 113
2022
Q1 		$320K Buy
3,260
+335
+11% +$28.2K 0.16% 109
2021
Q4 		$248K Buy
+2,925
New +$240K 0.12% 120

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Congress Park Capital's MDGL Position: Q2 2024 in Review

Congress Park Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 1,200 shares — an estimated $320K sold.

Congress Park Capital first reported a position in MDGL in Q4 2021 and held it in 6 quarters. The position peaked at $320K in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • Congress Park Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Congress Park Capital sold 1,200 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $320K.
  • Congress Park Capital first reported a position in Madrigal Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Congress Park Capital's Madrigal Pharmaceuticals position peaked at $320K in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Congress Park Capital's 13F filing for Q2 2024, filed 12 Jul 2024.